



Streptococcus Group A (3401): sc-58043

BACKGROUND

The *Streptococcus* bacterium exists in more than 20 serologic groups, based on differences in group-specific polysaccharides located in the bacterial cell wall. The groups are designated by letters. *Streptococcus* Group A (GAS) is a Gram-positive, non-spore-forming, non-motile organism that appears as pairs of short chains. *Streptococcus* Group A bacterium are responsible for most cases of streptococcal illness. Other groups (B, C, D and G) may also cause infection. Found to inhabit a wide range of hosts including humans, horses, porcines and bovines, *Streptococci* colonize the mucosal surfaces of the mouth, nose and pharynx. Severe GAS infections may lead not only to shock and multisystem organ failure, but also to death. Early recognition and treatment with the antibiotics of choice, penicillin, erythromycin and clindamycin, is critical. *Streptococcus* Group A causes a wide range of illness, from mild sore throats to life-threatening invasive disease.

REFERENCES

1. Amir, J., Rotman, M., Schwartz, K., Maayan, R. and Varsano, I. 1994. Evaluation of a rapid test to detect *Streptococcus* Group A. *Isr. J. Med. Sci.* 30: 617-619.
2. Kreis, U.C., Varma, V. and Pinto, B.M. 1995. Application of two-dimensional NMR spectroscopy and molecular dynamics simulations to the conformational analysis of oligosaccharides corresponding to the cell-wall polysaccharide of *Streptococcus* Group A. *Int. J. Biol. Macromol.* 17: 117-130.
3. Weimar, T., Harris, S.L., Pitner, J.B., Bock, K. and Pinto, B.M. 1995. Transferred nuclear Overhauser enhancement experiments show that the monoclonal antibody strep 9 selects a local minimum conformation of a *Streptococcus* Group A trisaccharide-hapten. *Biochemistry* 34: 13672-13681.
4. Stuike-Prill, R. and Pinto, B.M. 1995. Conformational analysis of oligosaccharides corresponding to the cell-wall polysaccharide of the *Streptococcus* Group A by Metropolis Monte Carlo simulations. *Carbohydr. Res.* 279: 59-73.
5. Auzanneau, F.I., Forooghian, F. and Pinto, B.M. 1996. Efficient, convergent syntheses of oligosaccharide allyl glycosides corresponding to the *Streptococcus* Group A cell-wall polysaccharide. *Carbohydr. Res.* 291: 21-41.
6. Chelsom, J. and Halstensen, A. 2001. *Streptococcus* Group A infections of skin, soft tissue and blood. *Tidsskr. Nor. Laegeforen.* 121: 3310-3314.
7. Gonzalez-Rey, C., Belin, A.M., Jorbeck, H., Norman, M., Krovacek, K., Henriques, B., Kallenius, G. and Svenson, S.B. 2003. RAPD-PCR and PFGE as tools in the investigation of an outbreak of β -haemolytic *Streptococcus* Group A in a Swedish hospital. *Comp. Immunol. Microbiol. Infect. Dis.* 26: 25-35.
8. Braitto, A., Galgani, I., Mohammed, M.R., Iozzi, C., Ame, S.M., Haji, H.S. and Zanchi, A. 2004. Epidemiology of *Streptococcus* Group A in school-aged children in Pemba. *East Afr. Med. J.* 81: 307-312.

SOURCE

Streptococcus Group A (3401) is a mouse monoclonal antibody raised against *Streptococcus* Group A whole cells fixed and digested to remove protein.

PRODUCT

Each vial contains 100 μ g IgM in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

Streptococcus Group A (3401) is recommended for detection of Streptococcus Group A by immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)] and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.